首页> 外文期刊>The Journal of Urology >Influence of prostate volume and percent free prostate specific antigen on prostate cancer detection in men with a total prostate specific antigen of 2.6 to 10.0 ng/ml.
【24h】

Influence of prostate volume and percent free prostate specific antigen on prostate cancer detection in men with a total prostate specific antigen of 2.6 to 10.0 ng/ml.

机译:总前列腺特异性抗原为2.6至10.0 ng / ml的男性中,前列腺体积和游离前列腺特异性抗原百分比对前列腺癌检测的影响。

获取原文
获取原文并翻译 | 示例
       

摘要

PURPOSE: Percent free prostate specific antigen and prostate specific antigen density have been independently shown to increase the specificity of prostate cancer screening in men with prostate specific antigen levels between 4.1 and 10.0 ng/ml. Recent data suggest the total prostate specific antigen cutoff for performing a biopsy should be 2.6 ng/ml. We assessed the influence of percent free prostate specific antigen and prostate volume on cancer detection in men with a prostate specific antigen between 2.6 and 10.0 ng/ml. MATERIALS AND METHODS: From 1991 to 2005 all transrectal ultrasound guided prostate biopsies (5,587) for abnormal digital rectal examination and/or increased age specific prostate specific antigen were evaluated. A total of 1,072 patients with a prostate specific antigen between 2.6 and 10.0 ng/ml and any percent free prostate specific antigen were included in study. The cancer detection rate was calculated for each percent free prostate specific antigen/volume stratum. RESULTS: Prostate cancer was detected in 296 patients (27.6%). The mean age and prostate specific antigen of the patients with benign pathology and prostate cancer were similar. Mean percent free prostate specific antigen was 17.5% and 14.1% (p>0.05), and the mean volume was 62.0 and 46.0 cc (p=0.001), respectively. The strongest risk factors for a positive biopsy were percent free prostate specific antigen (odds ratio 0.004, p<0.001), volume (OR 0.977, p<0.001) and digital rectal examination (OR 1.765, p=0.007), but not total prostate specific antigen (p=0.303). When stratified by volume and percent free prostate specific antigen, distinct risk groups were identified. The probability of detecting cancer inversely correlated with prostate volume and percent free prostate specific antigen. CONCLUSIONS: In men with prostate specific antigen levels between 2.6 and 10.0 ng/ml, the probability of detecting cancer was inversely proportional to prostate volume and percent free prostate specific antigen. This table may assistin predicting patient risk for harboring prostate cancer.
机译:用途:前列腺特异性抗原水平在4.1至10.0 ng / ml之间的男性中,游离前列腺特异性抗原的百分比和前列腺特异性抗原的密度已被独立地证明可以提高前列腺癌筛查的特异性。最近的数据表明,进行活检的总前列腺特异性抗原截止值为2.6 ng / ml。我们评估了前列腺特异性抗原在2.6和10.0 ng / ml之间的男性中游离前列腺特异性抗原百分数和前列腺体积对癌症检测的影响。材料与方法:从1991年至2005年,对所有经直肠超声引导的前列腺活检标本(5,587例)进行了数字直肠指检和/或年龄增长的前列腺特异性抗原的评估。研究共纳入1,072名前列腺特异性抗原在2.6和10.0 ng / ml之间的患者,以及任意百分比的游离前列腺特异性抗原。计算每个游离前列腺特异性抗原/体积层的百分数的癌症检测率。结果:296例患者中检出了前列腺癌(27.6%)。良性病理和前列腺癌患者的平均年龄和前列腺特异性抗原相似。平均游离前列腺特异性抗原百分比为17.5%和14.1%(p> 0.05),平均体积分别为62.0cc和46.0cc(p = 0.001)。活检阳性的最强危险因素是游离前列腺特异性抗原百分率(几率0.004,p <0.001),体积(OR 0.977,p <0.001)和直肠指检(OR 1.765,p = 0.007),但不是总前列腺特异性抗原(p = 0.303)。当按体积和游离前列腺特异性抗原的百分比分层时,确定了不同的风险组。检测癌症的可能性与前列腺体积和游离前列腺特异抗原百分率成反比。结论:在前列腺特异性抗原水平在2.6和10.0 ng / ml之间的男性中,检出癌症的可能性与前列腺体积和游离前列腺特异性抗原百分比成反比。该表可以帮助预测患者患有前列腺癌的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号